NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lo
Post# of 156
(Total Views: 105)
Posted On: 05/22/2024 4:41:27 PM
NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases
Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity necessary for movement, cognitive function and more. Clene’s CEO, Rob Etherington, highlighted that CNM-Au8 is tailored to address the central nervous system needs, targeting diseases like ALS and MS… Clinical trials of CNM-Au8 have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially ‘reversing the clock’ on what would be considered healthy aging. This breakthrough has the potential to significantly improve survival and quality of life for patients with neurodegenerative diseases, offering improvements in movement, speech and overall function,” a recent article reads. “Looking ahead, Clene Inc. aims to transform healthcare for individuals with neurodegenerative diseases through CNM-Au8. The company is working towards regulatory approvals to bring this groundbreaking treatment to market.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity necessary for movement, cognitive function and more. Clene’s CEO, Rob Etherington, highlighted that CNM-Au8 is tailored to address the central nervous system needs, targeting diseases like ALS and MS… Clinical trials of CNM-Au8 have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially ‘reversing the clock’ on what would be considered healthy aging. This breakthrough has the potential to significantly improve survival and quality of life for patients with neurodegenerative diseases, offering improvements in movement, speech and overall function,” a recent article reads. “Looking ahead, Clene Inc. aims to transform healthcare for individuals with neurodegenerative diseases through CNM-Au8. The company is working towards regulatory approvals to bring this groundbreaking treatment to market.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)